Please ensure Javascript is enabled for purposes of website accessibility

3 Trends Robinhood Investors Can't Stop Buying Into

By Sean Williams – Sep 17, 2020 at 5:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Young and novice investors love these high-growth opportunities.

This has been a wild year for Wall Street and investors. In roughly six months, we've witnessed two completely divergent markets. A five-week period during the first quarter saw the benchmark S&P 500 lose more than a third of its value, while the subsequent five-month period involved the broad-based index recouping all of its losses and hitting new highs.

If there's one thing this volatility has successfully done, it's bring short-term investors out of the woodwork. Online investing app Robinhood is a testament to this.

Robinhood, which is best-known for its commission-free trading platform and its gifting of free stock to new members, has been particularly successful at courting young and/or novice investors. The average age of its millions of members is just 31 years.

However, how young and novice investors see the investment landscape is often very different from how experienced investors choose to put their money to work. The following three trends represent potential high-growth opportunities that have, thus far, proved irresistible to Robinhood investors.

A gloved hand using scissors to trim a cannabis flower.

Image source: Getty Images.

Marijuana

Perhaps it's no surprise at all that marijuana stocks are a top investment trend among Robinhood investors. That's because younger adults express the highest favorability toward cannabis of all age groups. It also doesn't hurt that North America is the focus of the cannabis investment community.

Although Robinhood's leaderboard (i.e., the most-held stocks on the platform) remains fluid, Aurora Cannabis (ACB 3.88%), Canopy Growth, Cronos Group, and Aphria were the respective Nos. 12, 28, 33, and 34 most-held stocks on the entire platform to begin September.

While it's true that cannabis could be one of the fastest-growing industries in North America this decade, Robinhood's investing platform comes with a fatal flaw: Its investors can't buy over-the-counter stocks. Since marijuana remains illegal at the federal level, U.S. pot stocks that deal directly with the plant aren't able to uplist to major exchanges. This means many of the fastest-growing and most financially stable pot stocks can't be bought on the platform, leaving Robinhood investors with Canada's chronic underperformers.

In particular, Aurora Cannabis has been a big-time money loser for investors. Aurora recently announced that it would write down up to 1.8 billion Canadian dollars in goodwill and intangible assets, and earlier this year its board approved a $350 million (in U.S. dollars) at-the-market offering to raise capital. Aurora has been consistently diluting the daylights out of its shareholders for four years and counting.

A health worker administering a vaccine to an elderly patient.

Image source: Getty Images.

COVID-19 vaccine/diagnostics development

Another trend that's been an irresistible attraction for Robinhood investors is the race for a coronavirus disease 2019 (COVID-19) vaccine, as well as diagnostics that help detect the SARS-CoV-2 virus that causes the illness. As of the beginning of the month, Moderna (MRNA 1.96%), Inovio Pharmaceuticals, Sorrento Therapeutics, Novavax, and Gilead Sciences (GILD -0.06%) were the respective Nos. 17, 35, 77, 84, and 87 most-held stocks on the platform.

Perhaps no two are better known than Gilead Sciences and Moderna. Gilead has had early success with investigational drug remdesivir, which received emergency use authorization from the U.S. Food and Drug Administration for patients with moderate and severe infections. If Gilead's COVID-19 drug is successful in trials, it could bring in more than $7 billion a year. 

Meanwhile, Moderna offered encouraging early stage results of experimental vaccine mRNA-1273, with neutralizing antibodies found in patients of all three dosing tiers. Moderna has also been the recipient of a boatload of cash from the federal government thanks to a vaccine deal and Operation Warp Speed.

I can't say I'm a huge fan of the vaccine race, at least from an investment perspective. While there's little doubt that approved vaccines and diagnostics can generate billions of dollars in revenue, there'll be plenty of competition and eventual pricing pressure on these vaccines. What's more, these emotion-driven investments usually fade.

A Tesla Model S plugged in and charging.

A Tesla Model S plugged in and charging. Image source: Tesla.

Electric vehicles

A final trend that Robinhood investors can't stop buying into is electric-vehicle (EV) manufacturers. As of the beginning of September, Tesla (TSLA 1.85%), NIO, and Nikola were the respective fourth, 21st, and 36th most-held stocks on the platform.

With the younger generation caring more about global warming than other generations, it shouldn't be all that surprising that they're attracted to EVs. With a few exceptions, EV sales have been growing in the U.S. by a double-digit percentage from the previous year. It's looking like only a matter of time before we see the pendulum swing significantly toward EV sales, in relation to traditional combustion engine vehicles.

No shock that the most popular of the EV makers is Tesla. Robinhood investors love to chase top-performing stocks higher, and at one point following the EV giant's 5-for-1 split, it was up more than 1,000% over the trailing year. Tesla appears to be on track to manufacture over 500,000 vehicles in 2020, which might (and I use this word loosely) give the company a shot at a full-year generally accepted accounting principles (GAAP) profit.

However, like the other hot trends that Robinhood investors are chasing, I'm not exactly sold. I don't deny that EVs are the future, so much as the valuations assigned them (and especially Tesla) make zero sense. Tesla is priced as if it can maintain its first-mover advantage in a space where battery technology is improving and multiple vehicles are now available. Just as the marijuana bubble burst, I fear the same thing could happen to EV stocks.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences and Tesla. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$281.11 (1.85%) $5.10
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.30 (-0.06%) $0.04
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.21 (3.88%) $0.04
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.04 (1.96%) $2.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.